首页> 中文期刊> 《中国实用医药》 >坎地沙坦酯与培哚普利联合治疗对高血压患者尿微量白蛋白影响的临床观察

坎地沙坦酯与培哚普利联合治疗对高血压患者尿微量白蛋白影响的临床观察

             

摘要

Objective To evaluate the clinical effect of candesartan cilexetil and perindopril on urinary microalbumin in hypertension patients.MethodsThere were 150 patients with hypertension included in the study, 50 cases for each group: candesartan cilexetil 8 mg/d (groupCA), perindopril 4 mg/d (group PE), candesartan cilexetil 8 mg/d combined with perindopril 4 mg/d (CP group), blood pressure, urinary albumin were analyzed. ResultsGroup CP , group CA, group PE, the total effective rate was 90%, 74%, 72%.The CP group was better than group CA, group PE , there were statistically significant (P<0.05); three groups could reduce urinary albumin content; group CP reduced the urinary albumin significantly, which was better than that of group CA and group PE, there were statistically significant (P<0.05).ConclusionCandesartan cilexetil combined with perindopril can treat microalbuminuria for patients with hypertension effectively.%目的:评价坎地沙坦酯联合培哚普利治疗高血压患者尿微量白蛋白的临床疗效。方法高血压患者150例临床资料进行分析,分别使用坎地沙坦酯8 mg/d(CA组)、培哚普利4 mg/d(PE组)、坎地沙坦酯8 mg/d联合培哚普利4 mg/d(CP组),测定治疗前后的血压、尿微量白蛋白值。结果CP组、CA组、PE组的总有效率分别为90.00%、74.00%、72.00%, CP组疗效优于CA组和PE组,差异具有统计学意义(P<0.05);三组方案都可以降低尿微量白蛋白含量, CP组能显著减低尿微量白蛋白含量,优于CA组及PE组,差异均具有统计学意义(P<0.05)。结论坎地沙坦酯与培哚普利联合治疗高血压患者尿微量白蛋白具有良好效果。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号